Review
Immunology
Ahmadreza Khoshroo, Keyvan Ramezani, Niusha Moghimi, Moein Bonakdar, Nazanin Ramezani
Summary: Rheumatoid arthritis (RA), an autoimmune disease, is associated with bone deterioration, particularly erosion of periarticular cortical bone. There is a complex interaction between inflammation and bone destruction in RA. Biological and targeted medicines have modified RA's bone metabolism. This article discusses the pathomechanisms of bone structure involved in biological and targeted treatments for RA, as well as the clinical implications of disease-modifying antirheumatic drugs (DMARDs).
INFLAMMOPHARMACOLOGY
(2023)
Editorial Material
Rheumatology
Camilla R. L. Machado, Gary S. Firestein
Summary: Rheumatoid arthritis synovium contains fibroblast-like synoviocytes that are phenotypically and functionally heterogeneous. Advanced analyses have identified at least four distinct cell states, which are determined by the cells' location in the synovium, epigenetic imprinting, and the influence of microenvironment mediators.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Qingtai Meng, Monan Lin, Wuqi Song, Jiahui Wu, Guoding Cao, Ping Huang, Zaiyu Su, Wei Gu, Xueqing Deng, Peng Xu, Yi Yang, Hui Li, Hailiang Liu, Fengmin Zhang
Summary: The gut-joint axis plays a key role in the treatment of rheumatoid arthritis, and the novel photobiomodulatory therapy (PBMT) has therapeutic effects on RA and can restore gut microbiota homeostasis.
Article
Rheumatology
Andrei Barbulescu, Johan Askling, Katerina Chatzidionysiou, Helena Forsblad-d'Elia, Alf Kastbom, Ulf Lindstrom, Carl Turesson, Thomas Frisell
Summary: This study compared the use and effectiveness of baricitinib, tofacitinib, and biologic DMARDs (bDMARDs) in Swedish RA patients. The results showed that baricitinib had higher proportions of good EULAR response, HAQ-DI improvement, and CDAI remission compared to TNFi. Baricitinib also had better treatment responses compared to non-TNFi bDMARDs, while tofacitinib had similar responses to bDMARDs but slightly lower than baricitinib.
Article
Rheumatology
Farzin Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, Rishi J. Desai
Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Emilie Sapart, Tatiana Sokolova, Stephanie de Montjoye, Stephanie Dierckx, Adrien Nzeusseu, Aleksandra Avramovska, Patrick Durez
Summary: The study evaluated the use of glucocorticoids in patients with early RA and found that glucocorticoids were more prescribed in seronegative RA patients with higher inflammation levels. However, a 5-year follow-up showed that initiating glucocorticoid treatment did not provide additional benefits for disease control in the short and long term.
Article
Immunology
Juan He, Yu Li, Jian Chen, Qi Wu, Hongying Shan, Xiaocheng Wang, Miaomiao Zhang, Liping Nie, Qingwen Wang
Summary: Different subsets of CD8+ T cells are associated with clinical features and serological parameters in rheumatoid arthritis (RA). Naive CD8+ T cells are negatively correlated with disease activity, while CD8+ CD28-T cells and CD8+ CD27-T cells are positively correlated with disease activity. Activated CD8+ T cells and TCR gamma E+ CD8+ T cells may be involved in inflammation and lipid metabolism in RA.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Rheumatology
Heidi J. Siddle, Lara S. Chapman, Kulveer Mankia, Codruta Zabalan, Marios Kouloumas, Karim Raza, Marie Falahee, Joel Kerry, Andreas Kerschbaumer, Daniel Aletaha, Paul Emery, Suzanne H. Richards
Summary: The study identified the importance of understanding the risk, engaging in preventive interventions, and undergoing predictive testing for individuals at-risk of rheumatoid arthritis. However, barriers to engagement exist, intensified by the burden of uncertainty. It is urgently needed to identify optimal approaches for presenting risk information to support decision-making for individuals at-risk of RA.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Gregory McDermott, Ritu Gill, Staci Gagne, Suzanne Byrne, Weixing Huang, Xiaosong Wang, Lauren C. Prisco, Alessandra Zaccardelli, Lily W. Martin, Lucy Masto, Vanessa L. Kronzer, Nancy Shadick, Paul F. Dellaripa, Tracy J. Doyle, Jeffrey A. Sparks
Summary: The study investigates the demographic, lifestyle, and serologic risk factors associated with isolated rheumatoid arthritis (RA)-associated bronchiectasis (RA-BR) that is not caused by interstitial lung disease (ILD). The findings suggest that seropositivity, older age at RA diagnosis, and lower BMI at RA onset are associated with isolated bronchiectasis in RA that is not a result of ILD.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tomasz Wysocki, Agnieszka Paradowska-Gorycka
Summary: Rheumatoid arthritis is a common inflammatory arthritis in which tumor necrosis factor plays a key role. However, there is variation in response to TNF-targeting drugs, which may be influenced by genetic factors. The field of pharmacogenomics offers potential for developing novel prognostic tools.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Yuan Qu, Yang Fu, Yuan Liu, Chuanguo Liu, Bing Xu, Qian Zhang, Ping Jiang
Summary: Transient receptor potential cation channel subfamily V member 1 (TRPV1) has been found to play a role in immune regulation and its dysregulation affects the development of rheumatoid arthritis. Understanding the mechanism of TRPV1 can lead to the design of new drugs and improved treatment of RA.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Xanthe M. E. Matthijssen, Ellis Niemantsverdriet, Saskia Le Cessie, Annette H. M. Van der Helm-van Mil
Summary: This study found that the decrease of inflammatory features usually occurs simultaneously in patients with RA and undifferentiated arthritis, including in ACPA subgroups, but synovitis decrease typically precedes tenosynovitis decrease. Additionally, in ACPA-positive patients, synovitis decrease occurs before osteitis decrease.
Article
Immunology
Yunju Jeong, JooYeon Jhun, Seon-Yeong Lee, Hyun Sik Na, JeongWon Choi, Keun-Hyung Cho, Seung Yoon Lee, A. Ram Lee, Sang-Jun Park, Hyun Ju You, Ji-Won Kim, Myeong Soo Park, Bin Kwon, Mi-La Cho, Geun Eog Ji, Sung-Hwan Park
Summary: The study found significant differences in gut microbiota composition in patients with different RF levels, and B. longum RAPO may alleviate RA by inhibiting the production of IL-17, reducing inflammation, bone damage, and cartilage damage. Further investigation is needed to evaluate the safety and efficacy of B. longum RAPO in patients with RA and other autoimmune disorders.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Alexander Vugler, James O'Connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Elizabeth Hickford, Alexander Verbitsky, Xiaoyou Ying, Markus Rehberg, Bruce Carrington, Mark Merriman, Andrew Moss, Jean-Marie Nicholas, Phil Stanley, Sara Wright, Tim Bourne, Yann Foricher, Daniel Brookings, Helen Horsley, Matthias Herrmann, Srinivas Rao, Markus Kohlmann, Peter Florian
Summary: This article reports the discovery and development of a potent small molecule inhibitor of TNF, SAR441566, which has shown potential as a treatment option for chronic autoimmune diseases. By stabilizing an asymmetrical form of TNF and compromising its functions, SAR441566 offers a promising alternative to established biologic drugs targeting TNF.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pediatrics
Lili Ye, Yingying Jin, Hua Huang, Fei Ding, Xuemei Xu, Chenxi Liu, Shengfang Bao, Jing Wu, Yanliang Jin
Summary: This study explored the role of DKK-1 and SOST in the pathogenesis of JIA. It was found that plasma levels of DKK-1 were significantly higher in JIA patients, especially in those with HLA-B27 positivity. After treatment, DKK-1 levels decreased significantly. However, there was no significant change in SOST levels among different JIA subtypes, before and after treatment, and healthy controls.
PEDIATRIC RESEARCH
(2023)
Article
Chemistry, Medicinal
Shibin Zhao, Julian Maceren, Mia Chung, Samantha Stone, Raphael Geiben, Melissa L. Boby, Bradley S. Sherborne, Derek S. Tan
Summary: Antibiotic resistance is a major threat to public health, with Gram-negative bacteria presenting unique challenges due to their low permeability and efflux pumps. Limited understanding of the chemical rules for overcoming these barriers hinders antibacterial drug discovery. Efforts to address this issue, such as screening compound libraries and using cheminformatic analysis, have led to the design of sulfamidoadenosines with diverse substituents, showing potential utility in accumulation in Escherichia coli.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2024)
Article
Chemistry, Medicinal
Jichun Li, Qing Li, Shuai Xia, Jiahuang Tu, Longbo Zheng, Qian Wang, Shibo Jiang, Chao Wang
Summary: This study successfully developed a short peptide mimetic as a MERS-CoV fusion inhibitor by reproducing the key recognition features of the HR2 helix. The resulting 23-mer lipopeptide showed comparable inhibitory effect to the 36-mer HR2 peptide HR2P-M2. This has important implications for developing short peptide-based antiviral agents to treat MERS-CoV infection.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2024)
Article
Chemistry, Medicinal
Krista Jaunsleine, Linda Supe, Jana Spura, Sten van Beek, Anna Sandstrom, Jessica Olsen, Carina Halleskog, Tore Bengtsson, Ilga Mutule, Benjamin Pelcman
Summary: Beta(2)-adrenergic receptor agonists can stimulate glucose uptake by skeletal muscle cells and are therefore potential treatments for type 2 diabetes. The chirality of compounds has a significant impact on the activity of these agonists. This study found that certain synthesized compounds showed higher glucose uptake activity. These findings provide important information for the design of novel beta(2)AR agonists for T2D treatment.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2024)
Article
Chemistry, Medicinal
Xin Xu, Jia Chen, Guan Wang, Xiaojuan Zhang, Qiang Li, Xiaobo Zhou, Fengying Guo, Min Li
Summary: The study focuses on EZH2, a promising therapeutic target for various types of cancers. Researchers designed and synthesized a series of novel derivatives aiming to enhance the EZH2 inhibition activity. Among them, compound 28 displayed potent EZH2 inhibition activity and showed high anti-proliferative effects in lymphoma cell lines and xenograft mouse models. The study suggests that compound 28 has potential as a therapeutic candidate for EZH2-associated cancers.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2024)
Article
Chemistry, Medicinal
Wei Zhang, Wei Liu, Ya-Dong Zhao, Li-Zi Xing, Ji Xu, Rui-Jun Li, Yun-Xiao Zhang
Summary: This study developed a series of aromatic amide derivatives based on Rhein and investigated their inhibitory activity against alpha-Syn aggregation. Two of these compounds showed promising potential in treating Parkinson's disease by stabilizing alpha-Syn's conformation and disassembling alpha-Syn oligomers and fibrils.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2024)
Article
Chemistry, Medicinal
Mani Sharma, S. S. S. S. Sudha Ambadipudi, Neeraj Kumar Chouhan, V. Lakshma Nayak, Srihari Pabbaraja, Sai Balaji Andugulapati, Ramakrishna Sistla
Summary: Therapeutically active lipids in drug delivery systems can enhance the safety and efficacy of treatment. The liposome formulation created using synthesized biologically active lipids showed additive anti-cancer effects and reduced tumorigenic potential.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2024)